Toxicity of lactide in dogs after 2 and 13 weeks of daily oral dosing.
Two-week and 13-week studies were conducted to determine the toxicity of lactide when the compound is administered orally in gelatin capsules to beagle dogs. In the 2-week study, daily doses of 0, 10, 100, 400, 1000 and 2500 mg/kg body weight/day were administered to dogs of both sexes for 14 consecutive days. All dogs survived to the end of the study. Clinical signs consistent with irritation of the alimentary tract occurred in dogs in the 1000 and 2500 mg/kg dose groups. Reductions in body weight gain and in absolute and relative thymus weights were observed in the same two dose groups, and reductions in absolute and relative spleen weights were seen in the 2500 mg/kg dose group. These changes were considered to be secondary to the stress resulting from irritation of the gastrointestinal tract. Gross and microscopic lesions were indicative of irritation, and included dark foci and haemorrhage of the stomach lining, and erosion and ulceration of the stomach and the oesophagus. Also noted in all high-dose dogs was renal tubular regeneration, which may represent repair of previous necrosis of the tubular epithelium. In the 13-week study, no deaths occurred when dogs were given daily oral doses of 0, 4, 20 or 100 mg/kg body weight/day. No clinical signs of toxicity were observed, and the compound had no effect on body weights, food consumption, or any of the clinical chemistry, haematology or urinalysis parameters assessed. Gross and microscopic findings considered to be potentially related to lactide administration were minimal, and included a stomach focus in one dog of each sex in the 100 mg/kg group. The stomach focus in the 100 mg/kg female dog was manifested microscopically as a stomach ulcer. Based on these results, the primary toxic effect of lactide was considered to be irritation of the gastrointestinal tract, and the no-observed-adverse-effect level (NOAEL) after subchronic oral dosing in dogs was considered to be 100 mg/kg/day.
Hébert
C D
CD
Safety Assessment Division, Southern Research Institute, Birmingham, AL, USA.
Giles
H D
HD
Heath
J E
JE
Hogan
D B
DB
Modderman
J P
JP
Conn
R E
RE
D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004285:Dogs; D004334:Drug Administration Schedule; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D006403:Hematologic Tests; D019344:Lactic Acid / Q000097:blood / Q000633:toxicity* / Q000652:urine; D008297:Male; D009929:Organ Size / Q000187:drug effects
D019344:Lactic Acid